insights_auto
Outlook: 37.5% bullish·12.5% bearish
Go to analysischevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$234.83
arrow_upward
+1.29%(+3.00) 1D
Oct 19, 12:57:26 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$232.64
High
$235.62
Low
$231.26
Mkt. cap
31.42B
Avg. vol.
1.34M
Volume
367.71K
P/E ratio
39.97
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
Open
$232.64
High
$235.62
Low
$231.26
Mkt. cap
31.42B
Avg. vol.
1.34M
Volume
367.71K
P/E ratio
39.97
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
News Corp
·
56 minutes ago
Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%
The Business Journals
·
3 days ago
Alnylam founder's new biotech lands $200M in upsized IPO
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEOYvonne Greenstreet
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorBiotechnology
Websitealnylam.com